Precision medicine: Opportunities, possibilities, and challenges for patients and providers

Journal of the American Medical Informatics Association

Volumn 23, Issue 4, 2016, Pages 787-790

  Adams, Samantha A ^a   Petersen, Carolyn ^b  

^a TILBURG UNIVERSITY   (Netherlands)

^b MAYO CLINIC   (United States)

Author keywords

ELSI; Equity; Informed consent; Patient engagement; Precision Medicine; Privacy and data protection

Indexed keywords

ARTICLE; HEALTH EQUITY; HUMAN; INFORMED CONSENT; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PRIVACY; CONFIDENTIALITY; HEALTH CARE PERSONNEL;

CONFIDENTIALITY; HEALTH PERSONNEL; HUMANS; INFORMED CONSENT; PATIENT PARTICIPATION; PRECISION MEDICINE;

EID: 84981156631     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1093/jamia/ocv215     Document Type: Article

References (50)

1. National Institutes of Health. Precision Medicine Initiative. http://www.nih. gov/precisionmedicine. Accessed July 31, 2015.
2. National Research Council. Toward Precision Medicine: Building a Knowledge Framework for Biomedical Research and a New Taxonomy of Disease. Washington, DC: The National Academies Press; 2011.
3. Desmond-Hellmann S. Toward precision medicine: a new social contract? Sci Transl Med. 2012;4(129):129ed3.
4. Ciardiello F, Arnold D, Casali PG, et al. Delivering precision medicine in oncology today and in the future -the promise and challenges of personalized cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25(9):1673-1678.
5. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795.
6. Payne TH. Health information exchange: a path towards improving the quality and value of health care for patients. Testimony before the US Senate Committee on Health, Education, Labor & Pensions. Washington, DC, 10 June 2015. http://www.help.senate.gov/imo/media/doc/Payne2.pdf. Accessed July 31, 2015.
7. Bernstam EV, Denny JC, Frey L. Call for Papers: Special Issue on Precision Medical Informatics. http://jamia.oxfordjournals.org/sites/default/ files/JAMIA-Special-Issue-PrecisionMedicine%203.25.15_LOM_jd.pdf. Accessed June 24, 2015.
8. United States White House. Fact Sheet: President Obama's Precision Medicine Initiative. https://www.whitehouse.gov/the-press-office/2015/01/ 30/fact-sheet-president-obama-s-precision-medicine-initiative. Accessed August 15, 2015.
9. Kaplan B, Brennan P. Consumer informatics supporting patients as co-producers of quality. J Am Med Inform Assoc. 2001;8(4):309-316.
10. Kaplan B, Litewka S. Ethical challenges of Telemedicine and Telehealth. Camb Q Healthc Ethics. 2008;17:401-416.
11. Khoury MJ, Gwinn ML, Glasgow RE, et al. A population approach to precision medicine. Am J Prev Med. 2012;42(6):639-645.
12. Simonds NI, Khoury MJ, Schully SD, et al. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst. 2013;105(13):929-936.
13. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366(6):489-491.
14. Vedder A, Cuijpers C, Vantsiouri P, et al. The law as a 'catalyst and facilitator' for trust in e-health: challenges and opportunities. LIT. 2014;6: 305-325.
15. Adams SA, van Veghel D, Dekker L. Developing a research agenda on ethical issues related to using social media in healthcare: lessons from the first Dutch Twitter heart operation. Camb Q Healthc Ethics. 2015;24(3): 293-302.
16. Gazdar AF, Minna JD. Precision medicine for cancer patients: lessons learned and the path forward. J Natl Cancer Inst. 2013;105(17):1262-1263.
17. Rubin EH, Allen JD, Nowak JA, et al. Developing precision medicine in a global world. Clin Cancer Res. 2014;20(6):1419-1427.
18. Green RC, Lautenbach D, McGuire AL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015;372(5):397-399.
19. Green RC, Lautenbach D, McGuire AL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015;372(5):397-399.
20. Quinlivan JA, Battikhi Z, Petersen RW. What factors impact upon a woman's decision to undertake genetic cancer testing? Front Oncol. 2014;3:325.
21. Arias JJ, Karlawish J. Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet. Neurology. 2014;82(8): 725-729.
22. Rogith D, Yusuf RA, Hovick SR, et al. Attitudes regarding privacy of genomic information in personalized cancer therapy. J Am Med Inform Assoc. 2014;21(e2):e320-e325.
23. Lee SM. Your 23andMe DNA can be used in racist, discriminatory ways. Buzzfeed. July 22, 2015. http://www.buzzfeed.com/stephaniemlee/your-23andme-dna-can-be-used-in-racist-discriminatory-ways#.elEwwNqbbj. Accessed August 15, 2015.
24. Conrad P. The Medicalization of Society: on the Transformation of Human Conditions into Treatable Disorders. Baltimore, MD: Johns Hopkins University Press; 2007.
25. Miah A, Rich E. The Medicalization of Cyberspace. New York, NY: Routledge, 2008.
26. Lupton D. Quantifying the body: monitoring and measuring health in the age of mHealth technologies. Critical Public Health. 2013;23:393-403.
27. National Institutes of Health. Precision Medicine Initiative Infographic. http:// www.nih.gov/precisionmedicine/infographic-printable.pdf. Accessed July 31, 2015.
28. Rosenbaum L. The paternalism preference -choosing unshared decision making. N Engl J Med. 2015;373(7):589-592.
29. Payne TH, Corley S, Cullen TA, et al. Report of the AMIA EHR 2020 Task Force on the status and future direction of EHRs. J Am Med Inform Assoc.
30. Hood L, Auffray C. Participatory medicine: a driving force for revolutionizing healthcare. Genome Med. 2013;5(12):110.
31. Hess R, Bryce CL, Paone S, et al. Exploring challenges and potentials of personal health records in diabetes self-management: implementation and initial assessment. Telemed J E Health. 2007;13(5):509-517.
32. Holden RJ, Schubert CC, Mickelson RS. The patient work system: an analysis of self-care performance barriers among elderly heart failure patients and their informal caregivers. Appl Ergon. 2015;47:33-150.
33. Centers for Disease Control and Prevention. CDC Health Disparities and Inequalities Report -United States, 2013. MMWR. 2013;62(Suppl 3):1-189.
34. Kashyap MV, Nolan M, Sprouse M, et al. Role of genomics in eliminating health disparities. J Carcinog. 2015;14(6). doi: 10.4103/1477-3163.
35. Sankar P, Cho MK, Condit CM, et al. Genetic research and health disparities. JAMA. 2004;291(24):2985-2989.
36. Bayer R, Galea S. Public health in the precision-medicine era. N Engl J Med. 2015;373(6):499-501.
37. Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. Am J Prev Med. 2015. Advance access published, doi: 10.1016/j.amepre.201508.031.
38. Cooper LA, Ortega AN, Ammerman AS, et al. Calling for a bold new vision of health disparities intervention research. Am J Public Health. 2015; 105(Suppl 3):S374-S376.
39. Zettler PJ, Greely HT. The strange allure of state "right-to-try" laws. JAMA Intern Med. 2014;174(12):1885-1886.
40. Jacob JA. Questions of safety and fairness raised as right-to-try movement gains steam. JAMA. 2015;314(8):758-760.
41. Insel TR. The NIMH research domain criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395-397.
42. Christie GP, Patrick K, Schmuland D. Consultation for collective action on personalized health technology eliminating ethical, legal, and social barriers for individual and societal benefit. J Health Commun. 2015;20(8):867-868.
43. Middleton A, Morley KI, Bragin E, et al. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research. Eur J Hum Genet. 2016; 24(1):21-29.
44. May T. On the justifiability of ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. J Law Med Ethics. 2015;43(1):134-142.
45. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
46. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14(12):1060-1074.
47. Reeves A, Trepanier A. Comparison of informed consent preferences for multiplex genetic carrier screening among a diverse population. J Genet Couns. 2015, Advance access published July 16, 2015. doi: 10.1007/ s10897-015-9854-4.
48. Tait AR, Voepel-Lewis T. Digital multimedia: a new approach for informed consent? JAMA. 2015;313(5):463-464.
49. Bernhardt BA, Roche MI, Perry DL, et al. Experiences with obtaining informed consent for genomic sequencing. Am J Med Genet A. 2015; 167A(11):2635-2646.
50. Bradbury AR, Patrick-Miller L, Long J, et al. Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015;17(6): 485-492.